Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030

“GLP-1 analogues are reshaping diabetes and obesity care as innovation in drug delivery, expanding indications, and strong R&D pipelines drive explosive global demand.”

Boston, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The GLP-1 analogue market is experiencing rapid expansion as the world faces rising obesity and diabetes prevalence, alongside strong demand for effective metabolic therapies. According to BCC Research’s Global GLP-1 Analogues Market report, the market was valued at $54.8 billion in 2024 and is projected to reach $268.4 billion by 2030. It is growing at a remarkable CAGR of 30.6% from 2025 to 2030.

How is this report helpful?

Growth in the GLP-1 analogue market is being shaped by rising global incidence of diabetes and obesity, increasing awareness of treatment options, and a strong R&D pipeline delivering next-generation formulations. Innovations in oral and injectable delivery, expanded therapeutic uses, and improved patient adherence are accelerating market adoption across major regions.

The report offers profound insights into regulatory environments, clinical advancements, market restraints, and emerging opportunities. It also examines market share trends, pricing factors, competitive dynamics, and long-term outlook. It further outlines how companies are responding to rising demand through strategic alliances, product expansions and regional market penetration.

Investment/investors/finance angle

With one of the fastest CAGRs in the global pharmaceuticals sector (30.6%), GLP-1 analogues represent a transformative investment opportunity. High obesity rates, strong reimbursement frameworks, and expanded therapeutic indications are fueling exceptional revenue potential. Digital health integration, including telehealth, AI-driven weight management programs, and personalized metabolic care, further enhances the scalability of the market.

This report helps investors understand where value is shifting within the market, including the continued dominance of injectable GLP-1 therapies, the emergence of new oral formulations, and strong growth prospects across all key regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA). It also highlights how evolving clinical applications, selective generic activity and regulatory developments are shaping long-term investment strategies.

Request a sample copy of the global GLP-1 analogues market report.

Report Synopsis

Additional Insights:

• Teva Pharmaceuticals introduced the first FDA-approved generic version of Saxenda (liraglutide injection) in 2025, expanding treatment options for weight loss in adults and certain adolescents. This milestone represents Teva’s fifth first-to-market generic launch in 2025 and reinforces its complex generics presence under its Pivot to Growth strategy.

• Novo Nordisk received U.S. FDA approval in 2025 for a new Wegovy (semaglutide 2.4 mg) indication through an sNDA. The therapy is now approved for treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2–F3), alongside diet and physical activity.

• In 2024, Sanofi India Limited introduced Soliqua to the market after receiving marketing authorization from the Central Drugs Standard Control Organization (CDSCO). The medication is approved for adults with obesity and type 2 diabetes mellitus to help improve blood sugar control. Soliqua is prescribed as an add-on therapy for patients whose blood glucose levels are not adequately managed through diet, exercise or existing oral or injectable treatments.

Innovations:

• In May 2025, the FDA accepted an application for oral semaglutide (Wegovy) 25 mg for chronic weight management. If approved, this would become the first oral GLP-1 therapy specifically for obesity.

• In August 2025, Eli Lilly’s oral GLP-1 candidate, orforglipron, completed Phase 3 trials in obesity, demonstrating approximately 12% weight loss over 72 weeks in overweight and obese adults, even without dietary restrictions.

How is AI impacting the market?
AI is accelerating drug discovery and development in the GLP-1 analogue market by identifying new compounds and optimizing clinical trial design. It also enhances patient targeting and treatment personalization through advanced data analytics, improving outcomes and market efficiency. As AI adoption grows, it is becoming an increasingly valuable tool for improving development speed, clinical precision and long-term strategic planning across the GLP-1 competitive landscape.

For a detailed breakdown of AI’s influence on this space, access the full AI Impact on the GLP-1 Analogues Market - BCC Pulse Report.

Market leaders include:

• HANSOH PHARMACEUTICAL GROUP CO. LTD.
• LILLY USA LLC.
• NOVO NORDISK A/S
• SANOFI
• SHANGHAI BENEMAE PHARMACEUTICAL CORP.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.

Get your copy of the report directly from BCC Research.

To request more information or complete your purchase, connect with us at info@bccresearch.com.

About BCC Research

BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.

For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

BCC Research

Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, U.S.
Email: info@bccresearch.com
Phone: +1 781-489-7301

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.